Insider Buying: Vivani Medical, Inc. (NASDAQ:VANI) Director Buys $18,899.58 in Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams purchased 18,529 shares of the business’s stock in a transaction on Wednesday, April 9th. The shares were bought at an average cost of $1.02 per share, for a total transaction of $18,899.58. Following the purchase, the director now owns 13,822,919 shares of the company’s stock, valued at $14,099,377.38. This trade represents a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Gregg Williams also recently made the following trade(s):

• On Friday, April 11th, Gregg Williams bought 2,311 shares of Vivani Medical stock. The shares were purchased at an average price of $1.01 per share, with a total value of $2,334.11.
• On Monday, April 7th, Gregg Williams acquired 44,400 shares of Vivani Medical stock. The shares were acquired at an average price of $0.99 per share, with a total value of $43,956.00.
• On Friday, April 4th, Gregg Williams purchased 34,000 shares of Vivani Medical stock. The shares were acquired at an average cost of $0.99 per share, with a total value of $33,660.00.
• On Wednesday, April 2nd, Gregg Williams bought 2,000 shares of Vivani Medical stock. The stock was bought at an average price of $1.01 per share, with a total value of $2,020.00.

Vivani Medical Stock Up 1.0 %

Shares of NASDAQ VANI opened at $1.02 on Monday. Vivani Medical, Inc. has a fifty-two week low of $0.91 and a fifty-two week high of $2.09. The business has a 50 day moving average price of $1.09 and a two-hundred day moving average price of $1.19. The firm has a market cap of $60.42 million, a PE ratio of -2.27 and a beta of 2.76.

Vivani Medical (NASDAQ:VANI) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, analysts anticipate that Vivani Medical, Inc. will post -0.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Vivani Medical in a research note on Friday, April 4th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in VANI. Northern Trust Corp raised its stake in shares of Vivani Medical by 19.1% in the 4th quarter. Northern Trust Corp now owns 71,915 shares of the company’s stock valued at $83,000 after purchasing an additional 11,540 shares in the last quarter. Geode Capital Management LLC raised its stake in Vivani Medical by 4.6% during the third quarter. Geode Capital Management LLC now owns 342,891 shares of the company’s stock valued at $401,000 after buying an additional 15,008 shares in the last quarter. Wealthedge Investment Advisors LLC bought a new position in Vivani Medical during the 4th quarter worth approximately $43,000. Finally, Jane Street Group LLC acquired a new position in shares of Vivani Medical in the 4th quarter worth approximately $66,000. 6.78% of the stock is owned by institutional investors and hedge funds.

Vivani Medical Company Profile

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.